Singapore: Japanese major Takeda Pharmaceutical and NEUTEC Ä°LAÇ SANAYÄ° VE TÄ°CARET A.Åž (Neutec) announced that Takeda's wholly-owned subsidiary, Takeda GmbH, and Neutec have signed an agreement to obtain a select portfolio from Neutec, comprising 13 products in the gastroenterology, respiratory, metabolic and musculoskeletal therapeutic areas, through the acquisition of NEUTEC TOPLAM KALÄ°TE YÖNETÄ°MÄ° SANAYÄ° TÄ°CARET ANONÄ°M ŞİRKETÄ° (Toplam Kalite), a group company of Neutec in Turkey. The transaction is expected to be finalized during the first quarter of fiscal year 2015. Neutec is a leading pharmaceutical group in Turkey with a diverse portfolio and strong in-house R&D capabilities focused on differentiated and value-added branded generics, which have been responsible for the company's performance and sustained growth in recent years.

Closing of the acquisition is subject to the satisfaction of certain conditions precedent. Upon closing, Takeda would acquire the select Neutec portfolio in cash for up to Turkish Lira (TRL) 300 million including milestone payments. Under the agreement, the products will continue to be manufactured locally by Neutec. This acquisition is expected to support Takeda's growth strategy and enhance its position in Turkey, adding complementary products to its existing gastroenterology, respiratory, metabolic and musculoskeletal portfolio, particularly in acute and chronic diseases.

This transaction will also increase Takeda's investment in Turkey, where the company has been operating for the last five years, offering a portfolio of prescription drugs with well-known brands such as Pantpas (gastroenterology), Actos (diabetes) and Alvesco (respiratory) and Xefo Rapid (musculoskeletal). Takeda Ä°laç SaÄŸlık Sanayi Ticaret Åžirketi (Takeda Turkey) has over 130 employees within its two offices in this country.